A Patient's Guide To Radioisotopes in Prostate Cancer Care
- Radioisotopes are medicines that deliver radiation directly to cancer cells — like a guided missile — so the damage goes where it’s needed most.
- Unlike external radiation, which shines beams at the prostate or bones, these treatments travel through your bloodstream and find cancer where it has spread.
- There are two main types of radioisotopes used in prostate cancer treatment: Alpha emitters (like radium-223 or actinium-225) are more powerful but travel only the width of a few cells, causing intense damage to cancer in a very focused way. Beta emitters (like lutetium-177) release energy that travels a short distance — enough to affect a small group of cells while mostly sparing healthy ones.
- Most prostate cancers show high levels of a protein called PSMA on their surface. This makes them excellent targets for lutetium-177 PSMA therapy (brand name Pluvicto). The medicine combines lutetium-177 with a molecule that sticks to PSMA.
“Radioisotopes, unlike external beam radiation, which is delivered by a machine, are delivered through the bloodstream,” Dr. Mark Amsbaugh, a radiation oncologist at the University of Texas, Houston, tells SurvivorNet. “That usually means starting an IV in a clinic, and an infusion is given either through a syringe or an infusion pump to the patient.
Read MoreWhat Are Radioisotopes?
Radioisotopes are tiny atoms that release energy as they break down. Doctors have found ways to attach these atoms to molecules that specifically “home in” on prostate cancer cells. Once the radioactive medicine finds its target, it gives off radiation that damages the cancer cell from the inside. There are two main types of radioisotopes used in treatment:- Alpha emitters (like radium-223 or actinium-225) are more powerful but travel only the width of a few cells, causing intense damage to cancer in a very focused way. Alpha emitters also have a shorter path length than beta emitters.
- Beta emitters (like lutetium-177) release energy that travels a short distance—enough to affect a small group of cells while mostly sparing healthy ones.
Lutetium-177 PSMA: A Big Step Forward
Most prostate cancers show high levels of a protein called PSMA on their surface. This makes them excellent targets for lutetium-177 PSMA therapy (brand name Pluvicto). The medicine combines lutetium-177, a beta emitter, with a molecule that sticks to PSMA.
In clinical trials, this treatment helped men with metastatic castration-resistant prostate cancer (mCRPC) — a form that no longer responds to standard hormone therapy — live longer and feel better. It is now approved for use not only after chemotherapy but also earlier, after one line of hormone-targeted treatment. This means more patients may be able to benefit sooner.
What Is The Treatment Like?
To be eligible for this treatment, you’ll need a special scan called a PSMA PET/CT to confirm your cancer has the PSMA target. The medicine is given through an IV, usually once every six weeks, for several cycles. Most patients go home the same day.
Possible side effects include:
- Tiredness
- Nausea
- Dry mouth
- Low blood counts (anemia or low platelets)
For many patients, these side effects are milder than chemotherapy.
Radium-223: Targeting Cancer In The Bones
When prostate cancer spreads, it often goes to the bones. Radium-223 (brand name Xofigo) is an alpha emitter that naturally behaves like calcium. It travels to areas of active bone growth — exactly where prostate cancer causes damage — and delivers radiation right there.
Radium-223 is best for men whose cancer is mostly in the bones and who don’t have disease in organs like the liver or lungs. It not only relieves pain but has been proven to help men live longer.
What Is The Treatment Like?
Radium-223 is given as a quick injection once a month, usually for six months. Side effects may include mild nausea or diarrhea, and sometimes lower blood counts.
Doctors recommend bone-strengthening medicines (like denosumab or zoledronic acid) along with calcium and vitamin D to reduce the risk of fractures.
What About New Treatments Like Actinium-225?
Researchers are studying actinium-225 PSMA, another radioligand therapy. Because actinium releases alpha particles, it delivers very strong, focused radiation. Early studies show promising results — even for men whose cancer came back after lutetium-177.
For now, actinium-225 is mostly available through clinical trials or special access programs, but it represents an exciting option for the future.
Choosing The Right Treatment
Which treatment is right depends on your situation.
For PSMA-positive cancer that has spread to bones or lymph nodes, lutetium-177 PSMA is often the choice, sometimes even before chemotherapy.
When cancer is mainly in the bones, causing pain, but has not spread to organs, radium-223 may be a strong option.
When cancer has resisted other treatments, clinical trials with actinium-225 or other new radiopharmaceuticals may be considered.
Your oncology team will look at scans, lab results, symptoms, and previous treatments before recommending a path forward.
Questions To Ask Your Doctor
- Will I be radioactive after treatment and what safety steps should I take?
- How will I be monitored during treatment?
- How will treatment impact my daily life?
- What steps can I take to minimize side effects?
Content independently created by SurvivorNet with support from Novartis Pharmaceuticals Corp.
Learn more about SurvivorNet's rigorous medical review process.
